Research Article
BibTex RIS Cite
Year 2022, Volume: 5 Issue: 4, 1183 - 1189, 20.07.2022
https://doi.org/10.32322/jhsm.1129894

Abstract

Supporting Institution

YOK

Project Number

YOK

References

  • Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199-207.
  • Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2): an update. Cureus 2020; 12: e7423.
  • World Health Organization Press Conference. The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19. Available online: URL: https://www.who.int/ emergencies/diseases/novel-coronavirus-2019 (accessed on 18 May 2020).
  • Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514-23.
  • Zhu N, Zhang D, Wang W, et al. A Novel coronavirus from patients with pneumonia in China. N Engl J Med 2020; 382: 727-33.
  • Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 34: 101623.
  • Weiliang C, Li S, Lin C, et al. Clinical features, and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. medRxiv. URL: https://www.medrxiv.org/content/10.1101/2020.02.23.20026963v1
  • Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020; 92: 791-96.
  • Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577-82.
  • Eubank S, Eckstrand I, Lewis B, et al. Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand. Bull Math Biol 2020; 82: 52.
  • Lederman S, Yellin MJ, Krichevsky A, et al. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation(help). J Exp Med 1992; 175: 1091-101.
  • Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 2018; 131: 39–48.
  • Kared H, Martelli S, Ng TP, et al. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother 2016; 65: 441-52.
  • Lino VA, Santos SM, Bittencourt HN, et al. Quantification of CD8(+)CD38(+) T lymphocytes by flow cytometry does not represent a good biomarker to monitor the reactivation of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter 2011; 33: 268-73.
  • Jiang Y, Wei X, Guan J, et al. COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential. Clin Immunol 2020; 218: 108516.
  • Kazancioglu S, Yilmaz FM, Bastug A, et al. Lymphocyte subset alteration and monocyte CD4 expression reduction in patients with severe COVID-19. Viral Immunol 2021; 34: 342-51.
  • Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 2020; 221: 1762-9.
  • Almeida M, Cordero M, Almeida J, et al. CD38 on peripheral blood cells: the value of measuring CD38 expression on CD8 T-cells in patients receiving highly active anti-retroviral therapy. Clin Appl Immunol Rev 2002; 2: 307-20.
  • Kang CK, Han GC, Kim M, et al. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity. Int J Infect Dis 2020; 97: 313-21.
  • Mazzoni A, Salvati L, Maggi L, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest 2020; 130: 4694-703.
  • Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry Part A 2020; 97: 772-6.

Identification of lymphocyte subgroups with flow cytometry in COVID-19 patients

Year 2022, Volume: 5 Issue: 4, 1183 - 1189, 20.07.2022
https://doi.org/10.32322/jhsm.1129894

Abstract

Objective: We aimed to determine lymphocyte subgroups and activation status of flow cytometry in COVID-19 patients and examine their relationship with disease stage and length of hospital stay.
Material and Method: Forty patients were analyzed in this study and compared with the age and sex-matched 40 healthy controls. COVID-19 patients have split as early and advanced-stage diseases. Flow cytometry assay was performed to determine the counts of lymphocyte subsets and activation status. Total lymphocyte count was calculated and CD45 (cluster of differentiation), CD3, CD4, CD8, CD19, CD27, CD38, CD56, CD57, and IgD were studied on lymphocyte gate. T helper / T cytotoxic rates and length of hospital stay were recorded.
Results: The patients' CD3(+)CD4(+) ( T helper) count and CD27 expression on T cells counts were significantly lower, and CD57 expression on CD3(+)CD8(+) T cytotoxic cells were significantly higher (p<0.05) than the control group. When the patients were divided into early and advanced stages, it was observed that CD38 expression on T cells was significantly lower in advanced-stage patients (p< 0.05) Total lymphocyte count and CD3(+) T lymphocyte count were negatively correlated with the duration of hospitalization as statistically significant (p <0.05).
Conclusion: Our data showed that the SARS-CoV-2 primarily affects T lymphocytes. It was thought that this effect occurred by impairment of development and activation of T lymphocytes. There are some discordances among the studies on T lymphocytes in the literature.

Project Number

YOK

References

  • Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199-207.
  • Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2): an update. Cureus 2020; 12: e7423.
  • World Health Organization Press Conference. The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19. Available online: URL: https://www.who.int/ emergencies/diseases/novel-coronavirus-2019 (accessed on 18 May 2020).
  • Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514-23.
  • Zhu N, Zhang D, Wang W, et al. A Novel coronavirus from patients with pneumonia in China. N Engl J Med 2020; 382: 727-33.
  • Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 34: 101623.
  • Weiliang C, Li S, Lin C, et al. Clinical features, and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. medRxiv. URL: https://www.medrxiv.org/content/10.1101/2020.02.23.20026963v1
  • Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020; 92: 791-96.
  • Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577-82.
  • Eubank S, Eckstrand I, Lewis B, et al. Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand. Bull Math Biol 2020; 82: 52.
  • Lederman S, Yellin MJ, Krichevsky A, et al. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation(help). J Exp Med 1992; 175: 1091-101.
  • Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 2018; 131: 39–48.
  • Kared H, Martelli S, Ng TP, et al. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother 2016; 65: 441-52.
  • Lino VA, Santos SM, Bittencourt HN, et al. Quantification of CD8(+)CD38(+) T lymphocytes by flow cytometry does not represent a good biomarker to monitor the reactivation of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter 2011; 33: 268-73.
  • Jiang Y, Wei X, Guan J, et al. COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential. Clin Immunol 2020; 218: 108516.
  • Kazancioglu S, Yilmaz FM, Bastug A, et al. Lymphocyte subset alteration and monocyte CD4 expression reduction in patients with severe COVID-19. Viral Immunol 2021; 34: 342-51.
  • Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 2020; 221: 1762-9.
  • Almeida M, Cordero M, Almeida J, et al. CD38 on peripheral blood cells: the value of measuring CD38 expression on CD8 T-cells in patients receiving highly active anti-retroviral therapy. Clin Appl Immunol Rev 2002; 2: 307-20.
  • Kang CK, Han GC, Kim M, et al. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity. Int J Infect Dis 2020; 97: 313-21.
  • Mazzoni A, Salvati L, Maggi L, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest 2020; 130: 4694-703.
  • Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry Part A 2020; 97: 772-6.
There are 21 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Original Article
Authors

İlhami Berber 0000-0003-3312-8476

Nurcan Kırıcı Berber 0000-0001-8634-2543

Ahmet Sarıcı 0000-0002-5916-0119

Harika Gözükara Bağ 0000-0003-1208-4072

Soykan Biçim 0000-0001-7498-344X

Burhan Turgut 0000-0003-2902-9328

Furkan Çağan 0000-0002-2538-857X

Mehmet Ali Erkurt 0000-0002-3285-417X

Ayşe Uysal 0000-0002-5581-8104

Nihal Sümeyye Ulutaş 0000-0001-5768-9863

Emin Kaya 0000-0001-8605-8497

İrfan Kuku 0000-0001-6126-0816

Project Number YOK
Publication Date July 20, 2022
Published in Issue Year 2022 Volume: 5 Issue: 4

Cite

AMA Berber İ, Kırıcı Berber N, Sarıcı A, Gözükara Bağ H, Biçim S, Turgut B, Çağan F, Erkurt MA, Uysal A, Ulutaş NS, Kaya E, Kuku İ. Identification of lymphocyte subgroups with flow cytometry in COVID-19 patients. J Health Sci Med / JHSM. July 2022;5(4):1183-1189. doi:10.32322/jhsm.1129894

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].

The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912


Editor List for 2022

Assoc. Prof. Alpaslan TANOĞLU (MD)  

Prof. Aydın ÇİFCİ (MD)

Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)

Prof. Murat KEKİLLİ (MD)

Prof. Yavuz BEYAZIT (MD) 

Prof. Ekrem ÜNAL (MD)

Prof. Ahmet EKEN (MD)

Assoc. Prof. Ercan YUVANÇ (MD)

Assoc. Prof. Bekir UÇAN (MD) 

Assoc. Prof. Mehmet Sinan DAL (MD)


Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.